

Re-starting a study suspended as a result of Covid-19

Researchers wishing to re-start a study which was suspended by Covid-19, should email the JRO on uclh.rannd@nhs.net or make contact with their divisional research lead.

The JRO and divisional research lead will ask the UCLH Principal Investigator (PI) to confirm details of the re-start, including (but not limited to):

- the rationale for restarting the study, and their anticipated timelines
- alignment of the restart with the restart of clinical areas
- availability of patients and the plan for recruitment of patients
- have there been any amendments to the study (since it closed) and/or will amendments be required at UCLH
- do they have the capacity themselves (PI and research team) to restart
- is the sponsor aware and agrees with the restart at UCLH
- the use and external services and providers
- covid-19 measures required for patients and staff including travel to UCLH

The full list of confirmations can be found in Appendix 2 in the [SOP for restarting studies at UCLH](#).

Three types of consent will be required before a study is provided with a "green-light" to reopen at UCLH. These are from:

1. the division and JRO (through their assessment of the above)
2. UCLH service support functions such as pharmacy, radiology and imaging (which will be obtained by the JRO on behalf of the PI)
3. the sponsor

Once all these approvals are obtained, final confirmation is provided by the Research Covid-19 Response Group at UCLH. The JRO coordinator will summarise the study at the group and feedback to the PI soon after. Should the group confirm the study should start at UCLH, the JRO will issue a "green-light".

No study should re-start before a "green-light" is issued.

The list of divisional leads can be [accessed here](#).

The full process including roles and responsibilities, the necessary checks and decision making procedures can be [accessed here](#).